Apgdi Drug Patent Portfolio
Apgdi owns 2 orange book drugs protected by 23 US patents Given below is the list of Apgdi's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10058536 | Pharmaceutical composition containing mirabegron | 30 Sep, 2036 | Active |
| US10058536 | Pharmaceutical composition containing mirabegron | 31 Mar, 2036 | Active |
| US10842780 | Pharmaceutical composition for modified release | 28 Mar, 2030 | Active |
| US11707451 | Pharmaceutical composition for modified release | 28 Mar, 2030 | Active |
| US10842780 | Pharmaceutical composition for modified release | 28 Sep, 2029 | Active |
| US11707451 | Pharmaceutical composition for modified release | 28 Sep, 2029 | Active |
| US12059409 | Pharmaceutical composition for modified release | 28 Sep, 2029 | Active |
| US12097189 | Pharmaceutical composition for modified release | 28 Sep, 2029 | Active |
| US8772315 | Pharmaceutical composition for treating overactive bladder | 30 Apr, 2029 | Active |
| US8772315 | Pharmaceutical composition for treating overactive bladder | 30 Oct, 2028 | Active |
| US7342117 | α-form or β-form crystal of acetanilide derivative | 04 May, 2024 | Expired |
| US7982049 | α-form or β-form crystal of acetanilide derivative | 04 May, 2024 | Expired |
| US8835474 | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient | 04 May, 2024 | Expired |
| USRE44872 | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient | 04 May, 2024 | Expired |
| US7750029 | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient | 18 Dec, 2023 | Expired |
| US7342117 | α-form or β-form crystal of acetanilide derivative | 04 Nov, 2023 | Expired |
| US7982049 | α-form or β-form crystal of acetanilide derivative | 04 Nov, 2023 | Expired |
| US8835474 | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient | 04 Nov, 2023 | Expired |
| USRE44872 | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient | 04 Nov, 2023 | Expired |
| US6346532 | Amide derivatives or salts thereof | 27 Sep, 2022 | Expired |
| US6346532 | Amide derivatives or salts thereof | 27 Mar, 2022 | Expired |
| US6562375 | Stable pharmaceutical composition for oral use | 01 Aug, 2020 | Expired |
| US6699503 | Hydrogel-forming sustained-release preparation | 10 Sep, 2013 | Expired |
Latest Legal Activities on Apgdi's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Apgdi.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 May, 2024 | US10842780 |
| Patent eCofC Notification | 26 Mar, 2024 | US11707451 |
| Recordation of Patent eCertificate of Correction | 26 Mar, 2024 | US11707451 |
| Mail Patent eCofC Notification | 26 Mar, 2024 | US11707451 |
|
Email Notification
Critical
| 26 Mar, 2024 | US11707451 |
|
Recordation of Patent Grant Mailed
Critical
| 25 Jul, 2023 | US11707451 |
|
Email Notification
Critical
| 25 Jul, 2023 | US11707451 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 25 Jul, 2023 | US11707451 |
| Recordation of Patent eGrant | 25 Jul, 2023 | US11707451 |
| Patent eGrant Notification | 25 Jul, 2023 | US11707451 |
| Mail Patent eGrant Notification | 25 Jul, 2023 | US11707451 |
|
Electronic Review
Critical
| 25 Jul, 2023 | US11707451 |
|
Electronic Review
Critical
| 06 Jul, 2023 | US11707451 |
|
Email Notification
Critical
| 06 Jul, 2023 | US11707451 |
|
Issue Notification Mailed
Critical
| 05 Jul, 2023 | US11707451 |
Apgdi's Drug Patent Litigations
Apgdi's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 16, 2017, against patent number US6346532. The petitioner Sawai Pharmaceutical Co., Ltd., challenged the validity of this patent, with Astellas Pharma Inc. as the respondent. Click below to track the latest information on how companies are challenging Apgdi's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6346532 | October, 2017 |
Terminated-Denied
(04 May, 2018)
| Astellas Pharma Inc. | Sawai Pharmaceutical Co., Ltd. |
Apgdi Drug Patents' Oppositions Filed in EPO
Apgdi drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 17, 2013, by Huenges Martin/, Glas Holger. This opposition was filed on patent number EP08843784A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP09817723A | Sep, 2021 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP09817723A | Sep, 2021 | Brand Murray Fuller LLP | Granted and Under Opposition |
| EP09817723A | Sep, 2021 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Granted and Under Opposition |
| EP09817723A | Sep, 2021 | Hamm&Wittkopp Patentanwälte PartmbB | Granted and Under Opposition |
| EP09817723A | Sep, 2021 | Bülle Dr., Jan | Granted and Under Opposition |
| EP09817723A | Sep, 2021 | Sandoz AG | Granted and Under Opposition |
| EP08843784A | Jul, 2013 | Huenges Martin/, Glas Holger | Revoked |
Apgdi's Family Patents
Apgdi drugs have patent protection in a total of 31 countries. It's US patent count contributes only to 13.4% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Apgdi Drug List
Given below is the complete list of Apgdi's drugs and the patents protecting them.
1. Myrbetriq
Myrbetriq is protected by 21 patents, out of which 13 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10842780
(Pediatric)
| Pharmaceutical composition for modified release |
28 Mar, 2030
(5 years from now)
| Active |
| US11707451
(Pediatric)
| Pharmaceutical composition for modified release |
28 Mar, 2030
(5 years from now)
| Active |
| US10842780 | Pharmaceutical composition for modified release |
28 Sep, 2029
(4 years from now)
| Active |
| US11707451 | Pharmaceutical composition for modified release |
28 Sep, 2029
(4 years from now)
| Active |
| US12059409 | Pharmaceutical composition for modified release |
28 Sep, 2029
(4 years from now)
| Active |
| US12097189 | Pharmaceutical composition for modified release |
28 Sep, 2029
(4 years from now)
| Active |
| US8772315
(Pediatric)
| Pharmaceutical composition for treating overactive bladder |
30 Apr, 2029
(4 years from now)
| Active |
| US8772315 | Pharmaceutical composition for treating overactive bladder |
30 Oct, 2028
(3 years from now)
| Active |
| US7342117
(Pediatric)
| α-form or β-form crystal of acetanilide derivative |
04 May, 2024
(7 months ago)
| Expired |
| US7982049
(Pediatric)
| α-form or β-form crystal of acetanilide derivative |
04 May, 2024
(7 months ago)
| Expired |
| US8835474
(Pediatric)
| Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
04 May, 2024
(7 months ago)
| Expired |
| USRE44872
(Pediatric)
| Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
04 May, 2024
(7 months ago)
| Expired |
| US7750029 | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
18 Dec, 2023
(1 year, 4 days ago)
| Expired |
| US7342117 | α-form or β-form crystal of acetanilide derivative |
04 Nov, 2023
(1 year, 1 month ago)
| Expired |
| US7982049 | α-form or β-form crystal of acetanilide derivative |
04 Nov, 2023
(1 year, 1 month ago)
| Expired |
| US8835474 | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
04 Nov, 2023
(1 year, 1 month ago)
| Expired |
| USRE44872 | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
04 Nov, 2023
(1 year, 1 month ago)
| Expired |
| US6346532
(Pediatric)
| Amide derivatives or salts thereof |
27 Sep, 2022
(2 years ago)
| Expired |
| US6562375 | Stable pharmaceutical composition for oral use |
01 Aug, 2020
(4 years ago)
| Expired |
| US6346532 | Amide derivatives or salts thereof |
15 Oct, 2018
(6 years ago)
| Expired |
| US6699503 | Hydrogel-forming sustained-release preparation |
10 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Myrbetriq's drug page
2. Myrbetriq Granules
Myrbetriq Granules is protected by 8 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10058536
(Pediatric)
| Pharmaceutical composition containing mirabegron |
30 Sep, 2036
(11 years from now)
| Active |
| US10058536 | Pharmaceutical composition containing mirabegron |
31 Mar, 2036
(11 years from now)
| Active |
| US7342117
(Pediatric)
| α-form or β-form crystal of acetanilide derivative |
04 May, 2024
(7 months ago)
| Expired |
| US7982049
(Pediatric)
| α-form or β-form crystal of acetanilide derivative |
04 May, 2024
(7 months ago)
| Expired |
| US7342117 | α-form or β-form crystal of acetanilide derivative |
04 Nov, 2023
(1 year, 1 month ago)
| Expired |
| US7982049 | α-form or β-form crystal of acetanilide derivative |
04 Nov, 2023
(1 year, 1 month ago)
| Expired |
| US6346532
(Pediatric)
| Amide derivatives or salts thereof |
27 Sep, 2022
(2 years ago)
| Expired |
| US6346532 | Amide derivatives or salts thereof |
27 Mar, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Myrbetriq Granules's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List